Episomal fusion gene
AssigneesVib Vzw, K.U. Leuven Research & Development
InventorsJan Cools, Anne Hagemeijer, Peter Marynen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product.
Claims5
1-11. (canceled)
A method to inhibit a constitutively activated kinase expressed by a NUP214-ABL1 fusion gene.
The use of imatinib, or a pharmaceutically acceptable salt thereof, to treat a T-ALL type characterized by the presence of NUP214-ABL1 fusion gene.
The use of imatinib, or a pharmaceutically acceptable salt thereof, to treat a cancer that is characterized by the presence of a NUP214-ABL1 fusion gene.
Dependencies are inferred from the claim text.